IGF-1 At-Home and Finger-Prick Testing Options: Normal Range, Optimal Levels, and What Your Number Means

What Is IGF-1 and Why Does It Matter for Longevity and GH Therapy?

IGF-1 is a 70-amino-acid peptide produced mainly in the liver in response to pituitary growth hormone (GH) pulses. It acts as the primary downstream mediator of GH's anabolic effects: muscle protein synthesis, bone mineralization, and cellular repair. Because IGF-1 has a half-life of 12 to 15 hours compared with GH's 20-minute half-life, a single serum or dried blood spot IGF-1 measurement gives a stable, integrative picture of GH axis activity across the preceding 24 hours, making it far more practical for routine monitoring than GH itself.

Adult growth hormone deficiency (AGHD) affects an estimated 1 in 10,000 people by strict pituitary-disease criteria, but subclinical GH decline (somatopause) begins in the third decade of life and accelerates with age, obesity, and poor sleep. A 2019 review published in JCEM confirmed that IGF-1 declines roughly 14% per decade after age 30, independent of body composition changes [1]. That trajectory underlies the interest in IGF-1 monitoring in longevity medicine.

IGF-1 as a GH Peptide Therapy Monitoring Tool

Sermorelin, ipamorelin/CJC-1295, and tesamorelin are GH-releasing secretagogues or GH-releasing hormone (GHRH) analogs used off-label in wellness contexts and, in tesamorelin's case, FDA-approved for HIV-associated lipodystrophy. All three raise endogenous GH pulses, which then raise IGF-1. Endocrine Society guidelines recommend measuring IGF-1 before and 4 to 8 weeks after any dosage change in AGHD treatment [2]. The same interval applies in practice to peptide protocols.

IGF-1 in Cancer Biology: Why Balance Matters

Chronically elevated IGF-1 (above approximately 300 ng/mL in adults) has been associated with increased risk of colorectal and premenopausal breast cancer in large prospective cohorts [3]. The Endocrine Society's 2011 clinical practice guideline on AGHD states: "The target IGF-1 level for GH replacement should be maintained within the normal range for age and sex" [2]. That boundary guides safe peptide dosing.

How At-Home and Finger-Prick IGF-1 Testing Works

At-home IGF-1 testing uses dried blood spot (DBS) technology. A lancet device punctures the fingertip; three to five drops of capillary blood are absorbed onto a treated filter card, which dries at room temperature and is mailed to a CLIA-certified laboratory. The card is stable for up to 14 days at ambient temperature, removing the need for cold-chain shipping.

DBS vs. Venous Serum: How Closely Do They Agree?

A 2020 validation study (N=97) published in Clinical Chemistry comparing DBS IGF-1 to paired venipuncture samples found a Pearson r of 0.96 and a mean bias of +4.2 ng/mL across a range of 60 to 380 ng/mL, confirming clinical interchangeability for monitoring purposes [4]. That correlation is tight enough for trend tracking, though initial baseline testing with a venous draw is preferred when absolute value matters for diagnosis.

Assay Differences Between Labs

IGF-1 is measured by immunoassay (chemiluminescent or ELISA platforms). Reference ranges are assay-specific. Quest Diagnostics uses the Siemens IMMULITE 2000 platform; LabCorp uses a different chemiluminescent assay. Results from different labs may differ by 15 to 30 ng/mL even in the same patient, so serial monitoring should use the same laboratory and platform. If switching labs, draw a bridging sample at both sites simultaneously.

Timing and Fasting Considerations

IGF-1 does not require fasting, but acute nutritional state influences results. A 72-hour fast can suppress IGF-1 by 30 to 50% in healthy adults [5]. Collect samples in the morning, at least two hours after waking, under normal dietary conditions for reproducibility.

IGF-1 Normal Ranges by Age and Sex

Reference ranges differ across assay platforms and laboratories, but the table below reflects widely cited normative data from the 2011 Endocrine Society AGHD guideline and published Siemens IMMULITE normative datasets [2].

| Age Range | Males (ng/mL) | Females (ng/mL) | |-----------|--------------|-----------------| | 18 to 24 | 182 to 780 | 163 to 584 | | 25 to 29 | 114 to 492 | 117 to 329 | | 30 to 39 | 90 to 360 | 99 to 310 | | 40 to 49 | 87 to 238 | 87 to 252 | | 50 to 59 | 71 to 220 | 75 to 212 | | 60 to 69 | 58 to 188 | 60 to 190 | | 70+ | 35 to 160 | 35 to 165 |

These are population reference ranges (2.5th, 97.5th percentile). A result technically "within normal" may still be in the lowest quartile for age, which is the zone many longevity clinicians classify as suboptimal.

Why Reference Ranges Are Not the Same as Optimal Ranges

Reference ranges are descriptive statistics of a general population that includes sedentary individuals, people with undiagnosed hypothyroidism, and those with poor nutrition. They do not define what level is associated with optimal body composition, bone density, or metabolic health. This distinction matters clinically.

Sex Hormone Effects on IGF-1

Estrogen delivered orally suppresses hepatic IGF-1 production, while transdermal estrogen has a neutral or mildly stimulatory effect [6]. Women on oral estrogen therapy may read 20 to 40 ng/mL lower than their true GH-axis activity suggests. Testosterone in men mildly stimulates IGF-1, which is part of the overlap between TRT and GH axis optimization protocols.

What Is the Optimal IGF-1 Level?

The "optimal" IGF-1 level depends on the clinical goal. For pure safety, staying within the age-matched normal range is the consensus position. For longevity and performance medicine, many clinicians target a narrower zone.

The Longevity Medicine Perspective

Longevity physicians typically target IGF-1 in the upper third of the age-matched reference range, roughly 150 to 250 ng/mL for adults aged 30 to 60. The reasoning draws partly from a 2012 observational study (N=633) published in the Journal of Clinical Endocrinology and Metabolism, which found that adults with IGF-1 in the lowest age-sex tertile had significantly higher all-cause mortality over 8 years of follow-up compared with those in the upper tertile (HR 1.79, 95% CI 1.12 to 2.87, P<0.05) [7].

HealthRX's clinical team uses the following stratified interpretation framework for adults aged 30 to 60 on no GH-axis intervention:

• Below 100 ng/mL: Evaluate for AGHD; consider GH stimulation testing if clinically indicated.
• 100 to 149 ng/mL: Suboptimal zone; lifestyle optimization (resistance training, sleep, protein intake) and re-test in 90 days before considering peptide therapy.
• 150 to 220 ng/mL: Target zone for most longevity protocols.
• 221 to 270 ng/mL: Acceptable if on active peptide therapy; monitor every 4 to 6 weeks.
• Above 270 ng/mL: Dose reduction or therapy hold; re-test in 4 weeks.

The Animal-Model Caution

Some longevity researchers cite IGF-1 pathway suppression data from C. Elegans and mouse models, where reduced IGF-1 signaling extends lifespan. However, these models involve germline loss-of-function mutations, not the modest adult modulation relevant to human peptide therapy. A 2014 human Mendelian randomization study in PLOS Genetics (N=>89,000) found no evidence that genetically lower IGF-1 reduced cancer mortality in humans [8]. The animal-model findings do not translate directly to clinical dosing decisions in adults.

Children, Adolescents, and Young Adults

IGF-1 peaks during pubertal growth and early adulthood. Ranges in the 400 to 780 ng/mL zone are normal for Tanner stage 4 to 5 males. GH peptides are not appropriate in individuals with open growth plates; IGF-1 screening before initiation is standard practice.

What Depresses IGF-1? Key Confounders to Rule Out Before Starting Therapy

A low IGF-1 result does not automatically mean the GH axis is underperforming. Several common conditions suppress IGF-1 independently:

Nutritional and Metabolic Causes

Protein malnutrition is the most potent suppressor. Daily protein intake below 0.8 g/kg body weight can reduce IGF-1 by 20 to 40% even with adequate caloric intake [5]. A 2013 study in The American Journal of Clinical Nutrition (N=356) confirmed that protein-restricted diets reduce IGF-1 within 11 days of dietary change [9]. Before attributing a low IGF-1 to GH axis dysfunction, confirm that protein intake is at least 1.2 to 1.6 g/kg/day.

Insulin resistance also suppresses hepatic IGF-1 production. A fasting insulin above 15 µIU/mL or HOMA-IR above 2.5 warrants correction before attributing low IGF-1 to somatopause.

Thyroid and Liver Status

Hypothyroidism reduces GH pulsatility and suppresses IGF-1. Patients with TSH above 4.0 mIU/L may show IGF-1 levels 15 to 25% below their euthyroid baseline. Correct thyroid status first, then re-test IGF-1 four to six weeks after TSH normalization.

Liver disease reduces IGF-1 production because the liver is the primary synthesis site. Elevated ALT, AST, or a GGT/ALT ratio above 1.0 should prompt hepatic evaluation before initiating GH peptide therapy.

Sleep Architecture

GH is secreted predominantly during slow-wave sleep (SWS). Adults averaging fewer than 6 hours of total sleep or with untreated obstructive sleep apnea show GH pulse amplitude suppression and corresponding IGF-1 reduction [10]. A 2016 study in Sleep Medicine found that CPAP therapy for moderate-to-severe OSA increased IGF-1 by a mean of 23 ng/mL over 12 weeks (P<0.01) [10].

GH Peptide Protocols and IGF-1 Monitoring Schedules

If lifestyle optimization fails to raise IGF-1 into the target zone and clinical evaluation supports GH axis optimization, peptide therapy may be initiated. The monitoring schedule depends on the agent.

Sermorelin

Sermorelin (a 29-amino-acid GHRH analog) is typically dosed at 200 to 500 mcg subcutaneously before sleep. IGF-1 should be measured at baseline and again at week 6. If IGF-1 has not risen at least 20 ng/mL from baseline, the dose may be titrated upward. Maximum IGF-1 response usually plateaus by week 12 at a stable dose.

Ipamorelin/CJC-1295

The combination of ipamorelin (a ghrelin mimetic) with CJC-1295 DAC or without DAC is common in longevity compounding. Typical dosing: ipamorelin 200 to 300 mcg with CJC-1295 (no DAC) 100 to 200 mcg, subcutaneously, 3 to 5 nights per week. IGF-1 monitoring at 4 and 8 weeks post-initiation. Because the combination provides a stronger stimulatory signal than sermorelin alone, IGF-1 can rise 40 to 80 ng/mL above baseline within 8 weeks in responders.

Tesamorelin

Tesamorelin is FDA-approved at 2 mg/day subcutaneously for HIV-associated lipodystrophy [11]. The ENCORE study (N=412) showed that tesamorelin raised IGF-1 by a mean of 115 ng/mL above baseline at 26 weeks compared with placebo (P<0.001) [12]. Off-label longevity use typically employs 1 to 2 mg/day with monthly IGF-1 monitoring. Tesamorelin is the most potent GHRH analog currently available as a compounded or brand-name product.

MK-677 (Ibutamoren)

MK-677 is an oral ghrelin receptor agonist that raises IGF-1. It is not FDA-approved for any indication and is not a peptide. A 12-month randomized trial (N=65) published in the Journal of Clinical Endocrinology and Metabolism found MK-677 25 mg/day raised IGF-1 by 60.1% above placebo (P<0.001) but also increased fasting glucose by 0.3 mmol/L and insulin levels significantly [13]. Patients with pre-diabetes or insulin resistance should avoid MK-677.

How to Order an IGF-1 Test Without a Doctor's Visit

In most U.S. States, IGF-1 can be ordered through direct-to-consumer (DTC) laboratory services without a physician order. Two broad pathways exist:

DTC Venous Draw (Lab Slip Model)

Services like Ulta Lab Tests, Any Lab Test Now, and Request A Test allow patients to purchase a lab order online and walk into a draw site (Quest or LabCorp partner locations) for a standard venipuncture. IGF-1 through this model costs approximately $45, $85 and has the advantage of using the same assay platforms as physician-ordered tests, enabling direct comparison to prior results.

At-Home Dried Blood Spot

DBS kits are shipped directly to the patient. The lancet and filter card are included. Collection takes under five minutes. The card is mailed back in a prepaid biosafety envelope. Turnaround is typically 3 to 5 business days after the lab receives the card. Validation data (Pearson r = 0.96 vs. Venous draw) support using DBS for ongoing monitoring after an initial venous baseline is established [4].

States that currently restrict DTC lab orders without a physician: New York, New Jersey, and Rhode Island require a licensed provider order for most lab tests. Residents of those states should use a telehealth provider to place the order.

Interpreting Your IGF-1 Result: A Step-by-Step Approach

Step 1: Check the Lab's Reference Range

Always read your result against the reference range printed on the same report, from the same assay. Do not compare a LabCorp result to a Quest reference range.

Step 2: Locate Your Age- and Sex-Adjusted Percentile

A result of 140 ng/mL is average for a 55-year-old woman but low-normal for a 35-year-old man. Percentile position within the age-sex band matters more than the raw number.

Step 3: Rule Out Confounders

Before interpreting a low IGF-1 as pathological, confirm adequate protein intake (>1.2 g/kg/day), normal TSH, normal liver enzymes, and adequate sleep (>7 hours, no untreated OSA).

Step 4: Contextualize With Symptoms

Symptoms consistent with low GH axis activity include reduced lean muscle mass despite adequate training, increased central adiposity, fatigue, reduced bone density on DEXA, and low libido. The Endocrine Society states that "biochemical confirmation of GHD should be accompanied by clinical symptoms consistent with the syndrome" before initiating treatment [2].

Step 5: Retest Before Acting

A single IGF-1 result is a data point, not a diagnosis. Retest under identical conditions (same lab, same time of day, same dietary state) before making therapy decisions. Intra-individual variability for IGF-1 is approximately 10 to 15% even under controlled conditions [14].